FDA health-advancement office sets guidance agenda: what sponsors should read into it

What the agenda says

On 6 November 2026 the FDA published the guidance agenda of its Office of Health Advancement (OHA). It names four guidance priorities for 2026 and 11 topics for 2027-2028. The published description says the agenda covers combination products, emergency use authorisation, informed consent, paediatric research and orphan designation, and that the public is invited to comment.

The available record does not say which topics fall under the 2026 priorities and which under the later list. It also does not give the split of the 11 topics across the five areas, any target dates, or whether any item is a new draft or a revision of existing guidance. Teams should read the agenda page itself before drawing conclusions about specific documents.

Why it matters

A guidance agenda is a forward-looking signal. FDA guidance is generally non-binding and describes the agency's current thinking, but in practice it shapes how submissions are structured and how reviewers and inspectors frame their questions. An agenda tells sponsors where the agency intends to put its drafting effort, usually before any text exists.

The open comment invitation is the practical hook. Input at the agenda stage can influence which questions a guidance addresses, which is usually easier than trying to change a finished draft. The record does not give a comment deadline or docket details, so confirming those on the agency page is the first job.

Regulatory context

The five areas are not a tidy cluster. Combination products and emergency use authorisation are mostly product-pathway and lifecycle topics. Informed consent and paediatric research are about how studies are designed and run. Orphan designation is an early-development and incentives topic. Together they touch almost every stage from first-in-human planning to emergency deployment, which suggests the agenda will interest a broad audience.

The same day brought another FDA signal in a different area. A direct final rule updates nonclinical testing terminology so that nonclinical tests can include cell-based assays, organs-on-chips and computer models, as part of the agency's animal-reduction drive. According to the record, the rule does not mandate any method and does not change evidentiary standards. Nothing in the records links this rule to the OHA agenda, and the two should not be conflated. But both show the FDA clarifying its expectations in writing rather than leaving them to case-by-case review.

Elsewhere, regulators published reference material of a similar housekeeping kind. The MHRA released a list of UK reference medicines with data and market exclusivity expiry dates, with an explanatory note and a downloadable CSV. It also updated its guidance on notifying clinical investigations of medical devices, including the 60-day notice rule, fees and payment steps. The pattern is regulators making procedural expectations easier to find and plan around.

Who is affected

Sponsors of drug-device and biologic-device combinations should check whether the combination products items touch their classification, labelling or lifecycle questions. Developers of rare-disease products have an obvious interest in the orphan designation and paediatric research topics. The records do not say what the agenda will change in either area.

Timing matters for sponsors already running registrational programmes. Protara Therapeutics, for example, has pushed enrolment completion in its STARBORN-1 lymphatic malformations trial into early Q1 2027 and plans a rolling BLA in the second half of 2027. That is one company's plan, not evidence about the agenda's content. But it illustrates a general point: programmes now in late development will reach submission while the 2027-2028 topics are being drafted. Any resulting guidance could therefore arrive in the middle of a filing, and teams should be ready to compare their plans against draft text as it appears.

Clinical operations and ethics teams should watch the informed consent item. It is the one most likely to affect protocol templates and site documents across all therapeutic areas, though the record gives no detail on scope.

What to watch

First, the comment window: its length and docket mechanics are not in the records. Second, whether the 2026 priorities turn into draft guidance in the coming months, and which topics they cover. Third, how the agenda is revised: agendas are plans, and items can be reordered or dropped.

Finally, keep the scope in perspective. This is a list of intentions, not a policy change. No new obligation exists today because of it, and the useful work for regulatory affairs teams is to map the five areas against their own pipeline and decide where engagement is worth the effort.